Search Result

Results for "

solid tumours

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Calcium Channel (1) CD3 (1) CD47 (1) Complement System (1) DNA Alkylator/Crosslinker (1) Drug Derivative (1) HDAC (2) IGF-1R (1) Interleukin Related (1) PD-1/PD-L1 (8) Peptide-Drug Conjugates (PDCs) (1) PSMA (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (2)
By Research Areas:	Cancer (24) Inflammation/Immunology (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

HY-P991349

GNR-051	PD-1/PD-L1	Cancer
GNR-051 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. GNR-051 can be used in Solid tumours research .

HY-P991348

BAT-1306	PD-1/PD-L1	Cancer
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research .

HY-172320

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .

HY-P991457

AVE1642	IGF-1R	Cancer
AVE1642 is a human IgG monoclonal antibody (mAb) targeting CD221/IGF1R. AVE1642 delays growth of tumour xenografts and prolongs the survival of tumour-bearing nude mice. AVE1642 can be used in advanced solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-128470

Mitoquidone GR-30921	Drug Derivative	Cancer
Mitoquidone (GR-30921) is is the first member of a group of pentacyclic pyrroloquinones. Mitoquidone shows good activity in a range of experimental solid tumour models. Mitoquidone can be used for the research of anti-cancer .

HY-P991344

AMP-224	PD-1/PD-L1	Cancer
AMP-224 is a fusion protein targeting PD-L2. AMP-224 specifically binds to PD-1 T cells (chronically stimulated/exhausted T cells). AMP-224 can be used in Colorectal cancer and Solid tumours research .

HY-139453A

LP-284	DNA Alkylator/Crosslinker	Cancer
LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .

HY-P991391

COM902	Transmembrane Glycoprotein	Cancer
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .

HY-P991352

SG-001	PD-1/PD-L1	Cancer
SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research .

HY-13432

Nanatinostat 2 Publications Verification CHR-3996	HDAC Apoptosis	Cancer
Nanatinostat (CHR-3996) is a potent, class I selective and orally active HDAC inhibitor with IC₅₀s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat has low activity against HDAC5 (IC₅₀ of 200 nM) and HDAC6 (IC₅₀ of 2100 nM). Nanatinostat induces apoptosis in myeloma cells. Nanatinostat has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .

HY-13432A

Nanatinostat TFA CHR-3996 TFA	HDAC Apoptosis	Cancer
Nanatinostat (CHR-3996) TFA is a potent, class I selective and orally active HDAC inhibitor with IC₅₀s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat TFA has low activity against HDAC5 (IC₅₀ of 200 nM) and HDAC6 (IC₅₀ of 2100 nM). Nanatinostat TFA induces apoptosis in myeloma cells. Nanatinostat TFA has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .

HY-16215

Mipsagargin G-202	Peptide-Drug Conjugates (PDCs) PSMA Calcium Channel	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .

HY-P991438

XmAb-662	Interleukin Related	Cancer
XmAb-662 is a fusion protein targeting IL-12. XmAb-662 can be used in solid tumours research .

HY-P991390

BAT-6021	Transmembrane Glycoprotein	Cancer
BAT-6021 is a human monoclonal antibody (mAb) targeting TIGIT. BAT-6021 can be used in Solid tumours research .

HY-P991357

STT-001	PD-1/PD-L1	Cancer
STT-001 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. STT-001 can be used in Solid tumours research .

HY-P991367

ES004	CD47	Cancer
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .

HY-111786

LHC-165	Toll-like Receptor (TLR)	Cancer
LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors .

HY-P991354

GR-1405	PD-1/PD-L1	Cancer
GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .

HY-P991455

PTX-35	TNF Receptor	Cancer
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .

Cat. No.	Product Name	Target	Research Area

HY-172320

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .

HY-16215

Mipsagargin G-202	Peptide-Drug Conjugates (PDCs) PSMA Calcium Channel	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .

Cat. No.	Product Name	Target	Research Area

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

HY-P991349

GNR-051	PD-1/PD-L1	Cancer
GNR-051 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. GNR-051 can be used in Solid tumours research .

HY-P991348

BAT-1306	PD-1/PD-L1	Cancer
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research .

HY-P991457

AVE1642	IGF-1R	Cancer
AVE1642 is a human IgG monoclonal antibody (mAb) targeting CD221/IGF1R. AVE1642 delays growth of tumour xenografts and prolongs the survival of tumour-bearing nude mice. AVE1642 can be used in advanced solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991344

AMP-224	PD-1/PD-L1	Cancer
AMP-224 is a fusion protein targeting PD-L2. AMP-224 specifically binds to PD-1 T cells (chronically stimulated/exhausted T cells). AMP-224 can be used in Colorectal cancer and Solid tumours research .

HY-P991391

COM902	Transmembrane Glycoprotein	Cancer
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .

HY-P991352

SG-001	PD-1/PD-L1	Cancer
SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research .

HY-P991438

XmAb-662	Interleukin Related	Cancer
XmAb-662 is a fusion protein targeting IL-12. XmAb-662 can be used in solid tumours research .

HY-P991390

BAT-6021	Transmembrane Glycoprotein	Cancer
BAT-6021 is a human monoclonal antibody (mAb) targeting TIGIT. BAT-6021 can be used in Solid tumours research .

HY-P991357

STT-001	PD-1/PD-L1	Cancer
STT-001 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. STT-001 can be used in Solid tumours research .

HY-P991367

ES004	CD47	Cancer
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .

HY-P991354

GR-1405	PD-1/PD-L1	Cancer
GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .

HY-P99176

ATG-031 1 Publications Verification	Inhibitory Antibodies	Cancer
ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991455

PTX-35	TNF Receptor	Cancer
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99035

Naptumomab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: